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Prostate cancer (PCa) is the second most common diagnosed malignant disease in men worldwide. Although serum PSA test
dramatically improved the early diagnosis of PCa, it also led to an overdiagnosis and as a consequence to an overtreatment of patients
with an indolent disease. New biomarkers for diagnosis, prediction, and monitoring of the disease are needed. These biomarkers
would enable the selection of patients with aggressive or progressive disease and, hence, would contribute to the implementation
of individualized therapy of the cancer patient. Since the FDA approval of the long noncoding PCA3 RNA-based urine test for the
diagnosis of PCa patients, many new noncoding RNAs (ncRNAs) associated with PCa have been discovered. According to their
size and function, ncRNAs can be divided into small and long ncRNAs. NcRNAs are expressed in (tumor) tissue, but many are also
found in circulating tumor cells and in all body fluids as protein-bound or incorporated in extracellular vesicles. In these protected
forms they are stable and so they can be easily analyzed, even in archival specimens. In this review, the authors will focus on ncRNAs
as novel biomarker candidates for PCa diagnosis, prediction, prognosis, and monitoring of therapeutic response and discuss their
potential for an implementation into clinical practice.
1. Introduction
1.1. Prostate Cancer Diagnosis. The prostate is an exocrine
gland in the male reproductive system that is responsible
for the production of 50–70% of the seminal fluids. In men,
prostate cancer (PCa) is the secondmost common diagnosed
malignant disease and the sixth leading cause for cancer
related death among men worldwide, with an estimation of
899.000 new cases and 258.000 deaths in 2008 [1, 2]. The
rate of PCa diagnosis increased over the past decades due
to an aging population, increased awareness, and the use
of prostate-specific antigen (PSA) in serum for screening
and diagnosis [3]. Upon abnormal digital rectal examination
(DRE) and/or elevated serum PSA values, the diagnosis
of PCa is usually obtained by pathological evaluation of
transrectal ultrasound-guided prostate needle biopsies. How-
ever, this procedure is limited by false-negative biopsies and
overdiagnosis of clinically insignificant malignancies [4, 5].
PCa is a heterogeneous disease and the clinical behavior
ranges from slow-growing tumors with no or little clinical
significance to aggressive metastatic and lethal diseases. By
definition, clinically insignificant PCa does not contribute
to PCa mortality [6] and the treatment of indolent PCa can
result in side effects that reduce quality of life of the patient
for no or little benefit.
The use of biomarkers has the potential to improve the
diagnosis of cancer, especially to identify cancer at an early
stage of disease with potentially curative therapy options.The
currently used PSA test has some well-known limitations [7].
AlthoughPSA is prostate-specific, it is not cancer-specific due
to elevated levels of serum PSA under benign conditions, like
benign prostate hyperplasia, urinary retention, prostatitis,
trauma, or physical manipulation [7]. Approximately, 30% of
men with a serum PSA of 5–10 ng/mL and >50% of men with
a PSA>10 ng/mLwill have prostate cancer.More importantly,
clinical trials have shown that the PSA testing and screening
is associated with an overdiagnosis and as a consequence an
overtreatment of patients with indolent disease [4, 5, 8].
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One of the current clinical priorities includes the iden-
tification of biomarkers that discriminate between indolent
and aggressive PCa so that patients with an indolent dis-
ease with low risk of progression may better benefit from
avoiding unnecessary treatments. The aim should as well be
to identify patients with an aggressive, rapidly lethal PCa at
an early stage, for which potential curative therapy options
are available. Without any doubt, there is a need for new
diagnostic and predictive biomarkers, and these markers
would enable individualized therapeutic management for the
cancer patient.
1.2. Prostate Cancer Monitoring. Beside screening and diag-
nosis, serum PSA is currently also used for monitoring dis-
ease progression. PCa depends on androgen receptor activity
at all stages. Standard therapy of disseminated prostate cancer
in hormone-naive patients is based on androgen-deprivation
therapy or androgen receptor antagonists. Unfortunately,
successful treatment effects are often followed by recurrence
of PCa, resulting in the so-called castration-resistant prostate
cancer (CRPC). Currently, there are no curative treatments
for CRPC available. Docetaxel is the first-line chemother-
apy for CRPC, providing modest survival benefits [9–11].
Response to treatment is usually determined by changes
in serum PSA levels and reduction of tumor burden on
radiological scans. The response rate is ∼50%, and many
patients suffer from significant toxicity [9, 11]. Metastasis
and chemoresistance are reasons for the mortality of PCa
patients.There are advances in the development of alternative
effective therapies (e.g., abiraterone acetate, enzalutamide,
cabazitaxel, and radium-223), but there is still a lack of useful
biomarkers for the management or monitoring of patients
with CRPC. Absolute serum PSA values are not suitable
for and predictive of CRPC patients. Predictive biomarkers
would be used to identify patients who most likely benefit
from a particular treatment, enabling personalized medicine
and hence treatment failure including side effects could be
avoided.
1.3. Biomarkers. Theheterogeneous nature of PCa and CRPC
is coupled with genetic and epigenetic alterations that occur
during disease progression and response to therapy. These
changes can lead to the expression or production of novel
disease-specific macromolecules, which could serve as novel
biomarkers. Biomarkers are molecules that can provide
information about the disease. In general, beside their role
in diagnosis, they could be useful for the evaluation of the
disease predisposition, screening, prognosis, prediction of
drug response, monitoring, and pharmacodynamic proper-
ties (e.g., for a determination of the most effective dose)
in combination with clinical history and parameters [12].
Biomarkers should be detectable in tissue, obtained by biopsy
or surgical resection, or in bodily fluids like blood, urine, and
semen. Potential biomarkers can be specific cells, proteins
(enzymes, hormones, etc.), metabolites, DNA or an epige-
netic modification of DNA, and expression levels of (novel)
RNA transcripts, including noncoding RNAs (ncRNAs) [13].
Human prostatic acid phosphatase (PAP) was the first
reported biomarker for PCa [14]. Proteomics and genomic
technologies have enhanced the discovery of potential novel
candidates. Many excellent reviews have summarized novel
candidate biomarkers including proteins (e.g., 𝛼-methylacyl-
CoA racemase, endoglin, prostate-specific membrane anti-
gen [PSMA], caveolin-1, interleukin-6, CD147, TGF-𝛽 1, and
human kallikrein-2), genetic biomarkers (e.g.,TMPRSS2:ETS
gene fusions, BRCA1/2 mutations), epigenetic modification
(e.g., methylation of the glutathione S-transferase [GSTP1]
gene and histone modifications), and expression of (novel)
mRNA transcripts in PCa [6, 15–19]. Examples are shown in
Table 1. Despite technological advances that contributed to
the identification of novel biomarker candidates in serum, the
use of proteins as biomarkers is still limited by the wide range
of protein concentrations. In addition, it is often difficult to
detect low-abundant proteins, due to interfering compounds,
themasking effects of high-abundance proteins, high levels of
salts, and big variations between individuals [6]. In contrast,
for example, RNA-transcripts can be reproducibly detected
and quantified in all kinds of specimens, even when present
at very low levels due to possibility to include amplification
steps.
Common genetic alterations in tumors also have an
impact on specific noncoding RNAs (ncRNAs). NcRNAs
(e.g.,microRNAs) have received increasing attention of inves-
tigators as they can target multiple signaling pathways related
to tumor progression, invasion, metastasis, and chemore-
sistance. Recent evidence suggests that ncRNAs represent
useful and promising markers for diagnostic and prognostic
purposes alone or in addition to other candidate markers.
NcRNAs have the potential to improve the current tests or
even to be superior to established protein-based biomarkers.
Therefore, the authors of this review focus on ncRNAs and
discuss their potential as new biomarkers for PCa diagnosis,
prognosis, prediction, and monitoring of PCa patients.
1.4. Noncoding RNAs. Only about 25,000 protein-coding
genes (covering approximately 2% of the human genome)
have been recognized by the International Human Genome
Sequencing Consortium [20]. Most of the human genome
does not code for any protein and therefore is called noncod-
ing DNA (ncDNA). Most of the ncDNA, estimations ranging
from 60 to 90%, is transcribed into functional ncRNAs.These
ncRNAs are not translated into proteins [21, 22] but still act
as important mediators of gene regulation in physiological as
well as pathological processes. Cumulative evidence points
towards an important role of ncRNAs in cancer initiation,
development, and progression [22]. NcRNAs are classified in
small and long ncRNAs (lncRNA) based on their size and
function (Figure 1).
1.4.1. Long Noncoding RNAs. Long noncoding RNAs (lncR-
NAs) have a length greater than 200 nucleotides (nt) and are
located in the nucleus or in the cytoplasm. The number of
lncRNAs is not clear. It has been estimated that approximately
15,000 lncRNAs are present in the human genome, but
the GENCODE v19 catalog of human lncRNAs contains
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Figure 1:The human genome consists of approximately 2% protein-
coding sequences, which can be transcribed into messenger RNAs
(mRNAs) and then translated into proteins. The majority of the
human genome exists in nonprotein-coding DNA, which can be
transcribed in (functional) noncoding RNAs (ncRNAs). According
to their size and function, ncRNAs can be grouped into long
noncoding RNAs (lncRNAs) and small ncRNAs.The group of small
ncRNAs, which are less than 200 nucleotides (nt) in length, consists
of microRNAs (miRNAs), piwi-interacting RNAs (piRNAs), ribo-
somal RNAs (rRNAs), small Cajal body-specific RNAs (scaRNAs),
small-interfering RNAs (siRNAs), small nuclear RNAs (snRNAs),
small nucleolar RNAs (snoRNAs), and transfer RNAs (tRNAs).
Beside their biogenesis from hairpin precursor molecules, miRNAs
can also be derived from lncRNAs and snoRNAs (highlighted in
red).
13,870 lncRNA genes that produce 23,898 lncRNAs [23].
However, only a few lncRNAs are expressed in a cell type-
specific manner [24, 25]. Recent studies have demonstrated
that lncRNAs regulate many processes such as transcription,
translation, cellular differentiation, gene expression regu-
lation, cell cycle regulation, chromatin modification, and
nuclear-cytoplasmic trafficking [20, 26–28]. LncRNAs can
function as oncogenes or as tumor suppressors. Examples
for oncogenic lncRNAs are CDKN2B-AS1 (ANRIL), which is
described in tissue of melanoma and PCa, HOX antisense
intergenic RNA (HOTAIR), which was found in breast and
colon cancer, and CCAT1, which is increased in gastric
carcinoma tissue. LncRNAs that function as tumor sup-
pressors are, for example, growth arrest-specific 5 (GAS5),
which is aberrantly expressed in several cancers including
PCa and the pseudogene PTENP1 [20]. Several PCa-specific
lncRNAs have been identified, such as PCA3, PCAT1, and
PCGEM1. The identification and function of these PCa-
specific lncRNAs are excellently reviewed byWalsh et al. [23].
The most interesting lncRNA candidates as PCa biomarkers
are discussed in the chapter “lncRNAs and prostate carcino-
genesis” (see Section 2.1).
1.4.2. Small Noncoding RNAs. Small ncRNAs, in general,
have a size of less than 200 nucleotides. Based on their
size and function the small ncRNAs can be subdivided
into microRNAs (miR, miRNAs), piwi-interacting RNAs
(piRNAs), ribosomal RNAs (rRNAs), short interfering RNAs
(siRNAs), small Cajal body-specific RNAs (scaRNAs), small
nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs),
and transfer RNAs (tRNAs, Figure 1).
MiRNAs are the best characterized class of small ncRNA
transcripts. Currently, there are 2,578mature humanmiRNAs
listed in the miRBase catalog of human miRNAs (v20,
June 2013) [22, 29], and the number of identified miRNAs
is still rising. Many excellent articles have described the
biogenesis and function of miRNAs and their role in human
diseases such as cancer. MiRNAs are fragments of single-
stranded ncRNAs of 19–25 nt, derived fromhairpin precursor
molecules [30, 31]. They are reported to regulate more than
50% of all protein-coding genes in mammalian cells [31, 32].
Predominantly, they repress protein expression by inhibiting
translation or by degradation of the target mRNA [33]. Genes
can be targeted by multiple miRNAs and each miRNA is
able to target hundreds of mRNAs directly or indirectly.
According to their important role in the regulation of genes
that are involved in many physiological processes, it is not
of a surprise that they are also involved in the initiation and
progression of cancer [34].The dysregulation of miRNAs has
been demonstrated in all types of human malignancies. Like,
for proteins, both miRNAs with oncogenic functions, also
called oncomirs, and tumor suppressive miRNAs have been
found [34, 35]. The expression of miRNAs can be influenced
by chromosomal rearrangements (deletions, amplifications,
and mutations), by DNA methylation, or by other types of
transcriptional control.
It is becoming evident that also another class of small
ncRNAs, the small nucleolar RNAs or snoRNAs, may be
dysregulated in cancer. Most snoRNAs are ubiquitously
expressed and function in thematuration andmodification of
other ncRNAs such as rRNAs [36]. SnoRNAs can be divided
into two structural classes, C/D-box (SNORD) and H/ACA-
box (SNORA) RNAs [37]. Until now, approximately 400
snoRNA species have been identified in the human genome
[37]. It is also known that some miRNAs originate from
snoRNAs and these snoRNA-derived miRNAs are termed
sno-miRs, sno-miRNAs, or sdRNAs. Very recently it was
reported that snoRNAs and fibrillarin, which is an enzymatic
small nucleolar ribonucleoprotein (snoRNP), are frequently
overexpressed in human breast and prostate cancer tissues
[38]. Specific cancer-related snoRNA signatures in blood
were described for nonsmall-cell-lung cancer [37, 39]. Fur-
ther investigations are necessary to confirm these findings,
to describe the role of snoRNAs and sdRNAs in (prostate)
cancer, and to evaluate their potential as biomarker.
2. What Is Known about Noncoding
RNAs in Prostate Cancer?
2.1. Long Noncoding RNAs and Prostate Carcinogenesis. A
well investigated lncRNA in PCa is PCA3. PCA3 was found
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to be strongly overexpressed (66-fold in PCa tissue compared
to normal prostate tissue) in more than 95% of primary PCa
specimens andmetastasis [40, 41]. It is not expressed in other
normal human tissues and, therefore, PCA3 is so far the most
PCa-specific gene known. PCA3 can be identified in post-
DRE voided urine, and based on this it was claimed to be
a novel PCa biomarker. The PROGENSA PCA3 test is the
first FDA-approved urine-basedmolecular diagnostic test for
menwith elevated serumPSA and a previous negative biopsy.
A urine PCA3 score (PCA3-to-PSA ratio) with a cut-off of
≥35 had an average sensitivity of 66% and a specificity of
76% for the prediction of PCa at biopsy (area under the
curve (AUC) 0.75), while serum PSA had only a specificity
of 47% [18, 42]. The PCA3 score is not influenced by age,
inflammation, prostate volume, or 5𝛼-reductase inhibitors
[18]. The use of the PCA3 ncRNA as biomarker in clinical
practice has been extensively reviewed [18, 43]. However, in
independent studies, no significant association of PCA3 score
in urine with prognostic or predictive parameters was found.
Additional PCa-specific lncRNAs have been described
(Table 1). Overexpression of oncogenic lncRNAs may pro-
mote tumor-cell proliferation and metastasis, and aberrant
expression of lncRNAs in PCa is associated with disease
progression. The lncRNA metastasis-associated lung adeno-
carcinoma transcript 1 (MALAT1) is overexpressed in several
human cancers, including PCa. In primary PCa, MALAT1
overexpression is correlated with markers of poor prognosis
(high Gleason-score, higher tumor-node-metastasis (TNM)
stage, and serum PSA >20 ng/mL) and its expression sig-
nificantly increases from hormone sensitive PCa to CRPC
[44]. Small interfering RNA- (siRNA-) mediated knockdown
of MALAT1 in PCa cell lines 22Rv1 and LNCaP inhibits cell
growth, invasion, andmigration and results in cell cycle arrest
in the G0/G1 phase, demonstrating its functional role in PCa
[44].
The lncRNA prostate cancer associated ncRNA
transcript- (PCAT-) 1 is highly prostate-specific and is
upregulated in a subset of high-grade localized (Gleason-
score ≥7) and metastatic PCa [23]. PCAT1 induces cell
proliferation and has a repressive effect on gene expression,
for example, on the tumor suppressor BRCA2 [45]. By
Affymetrix array-based expression profile analysis 213
lncRNAs were found to be significantly differentially
expressed in PCa tissue compared to benign prostate tissue.
Based on these results, two novel clinically relevant lncRNAs
have been identified in PCa, PCAT6, and PCAT7. The
expression of both lncRNAs increased from normal prostate
tissue to primary to metastatic PCa [23]. Knockdown of
PCAT6 and PCAT7 reduces cell growth and soft agar colony
formation in LNCaP cells.
Second chromosome locus associated with prostate-1
(SCHLAP1) is a lncRNA that is highly expressed in 25%
of prostate tumors. SCHLAP1 expression is revealed as a
predictor for PCa aggressiveness, with highly significant
hazard ratios for predicting biochemical recurrence, clinical
progression, and PCa-specific mortality in a large cohort
of localized PCa (𝑛 = 235, median follow-up 8.1 years).
SCHLAP1 has the potential as prognostic marker due to a
significant association between biochemical recurrence and
overall survival and high expression levels of SCHLAP1 [23,
46].
The lncRNA prostate cancer gene expression marker 1
(PCGEM1) was first described by Srikantan et al. in 2000
[47]. Recently, Yang et al. reported about two lncRNAs,
prostate cancer noncoding RNA1 (PRNCR1) and PCGEM1.
PCGEM1 is overexpressed in more than half of PCa tissues
[48]. The authors reported that these lncRNAs regulate
AR-mediated gene transcription in PCa. In CRPC, both
lncRNAs PCGEM1 and PRNCR1 activate the transcription of
AR splicing variants, even in the absence of ligand binding
[23, 48]. However, Prensner et al. confirmed the association
of PCGEM1 and PRNCR1 with PCa, but the authors found
no interaction with AR or components of AR signaling.
Furthermore, they demonstrated that PCGEM1 and PRNCR1
are not useful as prognostic marker after analysis of 230 high-
grade PCa patients and their clinical outcome [49]. It is of
note that it is also recently reported that PCAT18 is a highly
prostate-specific transcript, upregulated in prostate cancer,
and that the expression of PCAT18 is induced by AR signaling
[50]. Furthermore the lncRNACBR3 antisense RNA 1 (CBR3-
AS1) has been reported to be associated with changes in AR
activity [51].
So, in addition to PCA3, several novel PCa-specific or
PCa-associated lncRNAs are on the horizon, but none of
these, so far,made it to a clinical test for PCa. In initial studies,
the presence of lncRNA fragments in blood specimens has
been analyzed. For example, MALAT1 levels in plasma were
determined and these were found to be able to distinguish
biopsy-positive from biopsy-negative PCa patients (AUC
0.767; 𝑃 < 0.001). However, the sensitivityof the plasma
MALAT1 test was 58.6% and therefore lower than that for
serum PSA [44]. Research concerning lncRNAs as biomark-
ers for PCa is still in its infancy, and further investigations
as well as large validation studies are necessary before a
translation into the clinical setting will be possible.
2.2. DysregulatedmicroRNAs in Cancer Tissue. ManymiRNA
profiling studies in PCa have been performed, using tech-
nologies such as microarray analysis and next-generation
RNA sequencing (NGS) [52]. These methods allow the
analysis of many miRNAs simultaneously, but because of
their low sensitivity and their high throughput-screening
nature a validation in independent samples using quantitative
technologies such as qRT-PCR is needed.
Some miRNAs (Table 1) have been shown to be dys-
regulated and functionally relevant in certain cancer types
[53, 54]. Volinia et al. reported about 21 miRNAs that were
upregulated in six solid cancer tissues [55]. MiR-21 is well
known to play an important role in normal and pathological
processes including development, inflammation, cardiovas-
cular function, and cancer. Many researchers found high
expression ofmiR-21 in almost all types of solid cancer tissues
including PCa and, therefore, it was classified as an oncomir
[56]. MiR-21 targets tumor suppressor genes, such as phos-
phatase and tensin homolog (PTEN), tumor suppressor gene
tropomyosin 1 (TPM1), programmed cell death 4 (PDCD4),
maspin, and reversion-inducing cysteine-rich protein with
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Kazalmotifs (RECK) [57–60].The activation ofmiR-21might
enhance general processes of tumor progression, invasion,
and metastasis [17]. Furthermore, Wang and Zhang reported
that miR-21 was elevated in serum of patients with breast
cancer, colorectal cancer, lung cancer, esophageal cancer, and
gastric cancer compared to healthy controls and concluded
that miR-21 has the potential as a broad-spectrum serum-
based biomarker for the detection of some solid cancers.
However, the authors found no correlation with gender,
clinical stage, and lymph node metastasis [61].
Zhang et al. [54] systematically reviewed 49 studies that
investigated the expression of miR-183 family members, con-
sisting of miR-96, miR-182, and miR-183 in different tumors
(HCC, gastric, pancreatic, colon, rectal, breast, gynecologic,
lung, bladder, and prostate cancer) compared to noncancer-
ous tissues. Several studies reported that these miRNAs are
directly involved in human cancer processes, such as cellular
differentiation, tumorigenesis, proliferation, apoptosis, and
metabolism [54, 62–64]. All miRNAs from the miR-182-96-
183 cluster, located on chromosome 7q32.2, were upregulated
in 14 human cancers. The miR-183 family members were
most upregulated in colorectal and prostate cancer tissue [65–
68], followed by bladder, lung cancer, and HCC tissue [54].
The results for breast and gastric cancer were inconsistent
and miR-183 was downregulated in osteosarcoma [69].These
miRNAswere so far not described in the circulation of cancer
patients, but higher levels of miR-96, miR-182, and miR-183
were found in urine specimens of bladder cancer patients
compared to healthy controls [70, 71].
Upregulation of miR-221 and miR-222 has been observed
in several cancer cells [72] and it is also reported that the
miR-221/miR-222 cluster is highly expressed in metastatic
CRPC tissue. A transient overexpression ofmiR-221/miR-222
in LNCaP cells promoted the development of a CRPC-like
phenotype. As a result of elevated expression of miR-221,
expression of many cell cycle genes was altered and pathways
promoting epithelial-to-mesenchymal transition (EMT)
and tumor metastasis were activated [72]. Upregulated
levels of circulating miR-221 were identified in serum of
PCa patients and also in serum or plasma of patients, for
example, with lung cancer, ovarian cancer, melanoma,
and lymphoma, compared to their healthy controls
[31, 73].
MiR-205 is frequently downregulated in different cancers,
including glioblastoma [74, 75],melanoma [76], breast cancer
[77, 78], renal cell carcinoma [79], and prostate cancer [80–
83]. The presence of miR-205 suppresses cell proliferation
and metastasis. In prostate cancer, miR-205 functions as a
tumor suppressor throughdownregulation ofmultiple targets
like BCL2 [81], protein kinase C epsilon [84], and androgen
receptor [85]. Genes regulated by miR-205 are enriched in,
for example, the MAPK/ERK, toll-like receptor, and IL-6
signaling pathways [85]. Furthermore, miR-205 is observed
to be downregulated in cells that have undergone EMT, a
process that is accompanied by a decrease in E-cadherin
and fibronectin expression [86]. Inversely, expression of
miR-205 is upregulated in mesenchymal cells that initiated
mesenchymal-to-epithelial transition (MET) associated with
an upregulation of E-cadherin and a reduction of tumor cell
migration and cell invasion [82, 85]. MiR-205 inhibits tumor
invasion through several pathways; for example, low-density
lipoprotein receptor-related protein 1 (LRP-1) promotes can-
cer cell migration and invasion by inducing the expression of
matrix metalloproteinases (MMP) 2 and 9 [87, 88]. Schaefer
et al. reported about an inverse correlation between prostate
tissue miR-205 levels and the occurrence of metastases and
shortened overall survival of PCa patients [66, 85].Wang et al.
confirmed these results and they reported a stronger down-
regulation of miR-205 in advanced and/or metastatic PCa
[89]. MiR-205 was significantly downregulated in serum of
breast cancer patients compared to healthy controls [90], but
studies on serum of PCa patients are lacking. Nevertheless,
circulating miR-205 may be a promising biomarker for PCa
prognosis.
In addition to miR-205, miRNAs from the miR-143/miR-
145 cluster are also downregulated in (prostate) cancer [91].
MiR-143 and miR-145 are transcribed after TGF𝛽1 pathway
activation and inhibition of this pathway will lead to a
decrease of these miRNAs [92, 93]. MiR-143 targets Kirsten
rat sarcoma viral oncogene homolog (KRAS), ELK1, myosin
6, B cell lymphoma 2 (BCL-2), and extracellular signal-
regulated kinase 5 (ERK). A loss ofmiR-143 expression causes
an upregulation of ERK5, which induces cell proliferation,
survival, and invasion and as a consequence it leads to
the development of more aggressive forms of PCa [92].
The downregulation of miR-145 also leads to enhanced cell
proliferation. MiR-145 targets MYO6 and fascin homolog 1
(FSCN1), proteins also associated with PCa progression [92].
Whether miR-143 and miR-145 can serve as biomarker for
PCa still has to be investigated.
While the above described miRNAs are dysregulated in
many types of cancer, some miRNAs seem to be tissue-
specific. MiRNA expression profiles specific for PCa have
been discovered [17, 55, 66, 91, 94–98]. These profiling
studies showed differences in the expression of miRNAs in
localized or metastatic prostate cancer compared to benign
prostate epithelium or BPH, but in these studies also a large
number of non-tissue-specific miRNAs were found. The first
profiling of miRNAs in PCa was published in 2007. Porkka
et al. [94] observed a downregulation of 37 miRNAs and an
upregulation for 14 miRNAs in PCa. Schaefer et al. identified
10 miRNAs (miR-16, miR-31, miR-125b, miR-145, miR-149,
miR-181b, miR-184, miR-205, miR-221, and miR-222) to be
downregulated and 5 miRNAs (miR-96, miR-182∗, miR-183,
andmiR-375) that were upregulated in PCa tissues compared
to the matched normal tissues [66]. Ozen et al. found a
widespread downregulation of miRNAs in prostate cancer
tissue [96] and Ambs et al. reported about miR-32 to be
upregulated in PCa tissue [95]. Many of these differentially
expressed miRNAs are described only in one study and, thus,
have to be validated in independent investigations.
2.3. Circulating microRNAs as Diagnostic and Prognostic
Biomarkers in Prostate Cancer. For most of the deregulated
miRNAs in tissue, it is still unclear whether they can serve
as novel diagnostic and/or prognostic biomarkers. However,
some of the dysregulated ncRNAs in cancer tissue can be
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analyzed in body fluids and are therefore promising as
putative biomarkers for PCa (Table 1).
MiRNAs can be released into the blood circulation
(Figure 2) as a result of apoptotic and necrotic cell death
as well as by active secretion [99]. Extracellular miRNAs
may be involved in cell-cell communication and immune
regulation [100]. Cell-free miRNAs are detectable in all body
fluids. This accessibility makes them attractive as promising
biomarker candidates for PCa, as well as for other malignan-
cies. Mitchell et al. showed that cell-free circulating miRNAs
are highly stable and reproducibly detectable in serum and
plasma of humans [101, 102]. The stability of miRNAs in
noncell environments (i.e., protection from RNase activity)
may be because they form complexes with RNA-binding
proteins such as AGO1, AGO2 or high-density lipoprotein
(HDL) for the transport of miRNAs to recipient cells via the
bloodstream (Figure 2). Beside other protective mechanism,
they are also incorporated in microvesicles, like exosomes
and apoptotic bodies [103–105]. Circulating miRNAs also
may originate from the tumor surrounding tissue, from
other tissues in the human body that are not involved in
cancer or from blood cells [106, 107]. Studies are ongoing to
characterize potential cancer-specific circulating miRNAs.
Some studies described an upregulation of miR-21, miR-
200c, and miR-375 in prostate cancer tissue compared to
nonmalignant prostate tissue [66, 95, 108, 109]. Higher levels
of miR-21, miR-141, miR-200a, miR-200b, miR-200c, and/or
miR-375 were also observed in serum, plasma, or circulating
microvesicles in patients with metastatic disease compared
to localized PCa or healthy controls [109–113]. The latter
findings suggest that these miRNAs are derived from tumor
tissue and may act as circulating miRNA biomarkers for
the detection of metastatic disease. Circulating miRNAs
can originate from tumor cells, from other affected organs
involved in tumor invasion and metastasis, or from inflam-
matory responses [114]. MiRNAs have been associated with
prostate cancer; for example, miR-21 and miR-221 and their
deregulation were described in tumor tissue [55, 66, 94, 95,
98] and serum of PCa patients [110, 115, 116]. The differences
in serum miRNA levels between PCa patients (𝑛 = 51) and
healthy controls (𝑛 = 20) were highly significant for miR-21
(𝑃 < 0.001, AUC 88%) and for miR-221 (𝑃 < 0.001, AUC
83%). In patients with metastatic disease the serum levels
of miR-21, miR-221, and miR-141 (𝑃 < 0.001, AUC 75.5%)
were significantly higher than in patients with a localized
PCa [115]. Furthermore, circulatingmiR-21 andmiR-221 were
reported to discriminate PCa patients with intermediate risk
from those with low risk CAPRA scores with a sensitivity of
38.1% and a specificity of 94.2% (AUC 0.801) [116].
Across independent studies, circulating miR-141 and
miR-375 were the most promising miRNAs, suggested as
diagnostic and prognostic markers for high risk PCa, and
two miRNAs that were also decribed to be higher expressed
in prostate cancer tissue compared to nonmalignant prostate
tissue [66, 91, 95, 113]. Four independent studies analyzed
circulating miRNA levels in about 240 PCa patients and 70
healthy controls in total and found either miR-141 or miR-375
or both as a diagnostic and prognostic marker(s) [17, 101, 113,
115, 117]. Mitchell et al. [101] reported, as the first, that tumor-
derived miRNAs can enter into the circulation and can be
measured in serum and plasma as a blood-based biomarker
for human cancer. They observed that circulating miR-141
was significantly elevated in sera of prostate cancer patients
(sensitivity 60%, specificity 100%) [101]. Brase et al. confirmed
that circulating miR-141 and miR-375 were highly detectable
in serum from patients with an advanced disease, and their
levels correlated with high-risk tumors (Gleason-score ≥8 or
metastasis) [113].
Independent studies evaluated the increased serum levels
of miR-141 in patients with aggressive PCa [113, 115, 118, 119],
indicating its diagnostic potential. However, Westermann
et al. recently analyzed serum miR-141 in a multicenter
study and reported that miR-141 did not qualify as an early
diagnostic marker for PCa (AUC 0.49). In this study, serum
samples were collected from 170 patients who underwent
a prostate biopsy, of which 54 patients were diagnosed
with PCa. MiR-141 levels were not increased in serum from
patients with evident PCa compared to patients with a
PCa-negative biopsy, but the authors reported that miR-
141 levels were significantly increased in patients with a
higher Gleason-score (𝑃 = 0.049). However, there was
no association with clinical tumor stage or PSA [120]. The
function of miR-141 and miR-375 in prostate cancer is still
unclear. Waltering et al. found that miR-141 was upreg-
ulated by androgens and that an overexpression of miR-
141 in LNCaP cells increased cell proliferation, suggesting
that miR-141 could be involved in PCa progression [121].
Recently, it was reported that upon androgen treatment
increased levels of miR-141 and miR-375 were released in
the cell culture medium of LNCaP cells [122]. The authors
concluded that an increased release of miR-141 and miR-
375 from androgen-stimulated cells may explain their higher
levels in the blood of patients with advanced PCa or CRPC
[122, 123].
Beside single miRNAs, Chen et al. reported about a panel
of five circulating miRNAs (miR-30c, miR-622, miR-1285,
miR-let7c, and miR-let-7e) to discriminate PCa from healthy
individuals and BPH patients with a sensitivity of 61% to
90% and a specificity of 57% to 75%, respectively (PCa versus
healthy control AUC 0.86 and PCa versus BPH AUC 0.924)
[124].
Larne et al. [68] identified fourmiRNAs that discriminate
PCa from nonmalignant tissue. They combined these four
miRNA levels into a miRNA index quote (miQ): (miR-96-5p
× miR-183-5p)/(miR-145-5p × miR-221-5p). The advantages
of such a miQ are the increased discriminatory power of
the test and omitting the need for housekeeping genes. The
describedmiQ test predicts the presence of PCa (𝑃 < 0.0001)
with high accuracy (AUC 0.931), which was verified in four
independent cohorts. miQ has also a prognostic power to
predict aggressiveness of tumors (AUC 0.895), metastatic
status (AUC 0.827), and overall survival (𝑃 = 0.0013, hazard
ratio 6.5) [68]. In this pilot project, miQ was used with
miRNAs identified in tissue specimens, but it has also the
potential for analysis of a panel of miRNAs in serum/plasma
and urine. The value of miQ as a PCa biomarker has to be
validated in independent multicenter validation studies.
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Figure 2: microRNAs can be released from normal and malignant cells in the blood circulation. This process can be passive, for example,
after apoptosis, or as active secretion. In plasma or serum, cell-free microRNAs are protected against RNase activity, for example, through
their binding to AGO1, AGO2 proteins or to high density lipoproteins. Furthermore, microRNAs can also be incorporated intomicrovesicles,
such as exosomes, apoptotic bodies, or circulating tumor cells (CTCs). Specific microRNAs released from prostate cancer cells in body fluids,
such as blood or urine, can serve as novel biomarkers for diagnosis, prognosis, prediction, or monitoring of cancer patients.
In recent investigations, additional up- or downregulated
miRNAs in serum or plasma were described. Most of these
miRNAs were only reported in one study, and therefore
large validation studies are needed to verify these putative
candidates [112, 116, 124–130].
In summary, miR-141 and miR-375 are the most consis-
tently reported circulating miRNA candidates to be associ-
atedwith high risk PCa.However, inconsistent findings based
on miRNA levels are also notable. Major reasons for the
variations and the lack of consistency in the data of circulating
miRNAs are potentially variability in methodology of extrac-
tion and quantification of (micro) RNAs and data analysis
[131]. There is no consensus on suitable reference RNAs that
could be used as internal controls. Current protocols, using
spiked-in synthetic nonhuman (e.g., Caenorhabditis elegans)
miRNAs only correct for technical variability [101, 132]. Fur-
thermore, contamination of miRNAs due to haemolysis or
during sample processing is possible. The studies, published
until now, are a solid basis for discovery and establishing
new biomarkers in PCa, but for further studies better, widely
accepted, standardization, and normalization protocols are
needed.
2.4. Urinary microRNAs as Diagnostic and Prognostic
Biomarkers. Due to its noninvasive and easily attainable
nature, urine is a promising substrate for biomarker testing.
It is known that prostate cells and ncRNAs can be directly
released into the urethra through the prostatic ducts after
DRE. Cellular and extracellularmiRNAs in urine and urinary
microvesicles may be derived from urological cancers (e.g.,
prostate, bladder, or renal cancer), but they can originate
from normal epithelium, the glomerulus, or renal tubules
[133]. Therefore, specific markers and good normalization
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procedures are needed. The PROGENSA urine test for PCa
makes use of such a PCa-specific biomarker, the PCA3
lncRNA, and a normalization procedure using the prostate
epithelium-specific marker KLK3 (see Section 2.1).
Until now, only 4 studies reported miRNA levels in
urine of PCa patients [112, 134–136]. Bryant et al. found
that miR-107 and miR-574-3p were present at significantly
higher levels in urine of men with PCa compared to controls
[112]. Srivastava et al. analyzed miR-205 and miR-214 in
tissue and urine of PCa patients and reported that these
two candidates were present in detectable levels in urine
samples but significantly lower in the cancer group compared
to healthy controls. In this study, urinary miR-205 and miR-
214 were able to discriminate PCa patients and healthy
controls with 89% sensitivity and 80% specificity [134]. In a
profiling study using microarray analysis and validation by
qRT-PCR, miRNA levels in whole urine of PCa patients were
compared to patients with BPH and healthy controls. The
investigators identified miR-1825 and miR-484 as potential
urinary biomarkers for PCa diagnosis [135]. Unfortunately,
this study was limited by a very small number of samples (8
PCa patients, 12 BPH patients, and 10 healthy men) [135]. In
a profiling study, Sapre et al. identified miR-16, miR-21, and
miR-222 as predictors of high risk PCa, but the authors were
not able to validate the results in an independent cohort [136].
Due to their high stability and easy detection, urinary
miRNAs have a high potential to become noninvasive
biomarkers. Further investigations, using standard proce-
dures for preanalytical processing and data normalization,
followed by validation of candidate miRNAs in large clinical
trials are required to translate incidental finding(s) into a
clinically applicable test.
2.5. microRNAs as Predictive Biomarkers in Prostate Can-
cer. MiRNAs have also the potential to serve as predictive
markers. In a profiling study, Selth et al. detected increasing
levels of three circulating miRNAs (miR-141, miR-146b-3p,
and miR-194) in serum of patients who experienced a rapid
biochemical recurrence after radical prostatectomy, but only
miR-146b-3p and miR-194 were also associated with disease
progression in a validation cohort [119]. Santos et al. found
higher levels of miR-221 and miR-7 in blood of patients
diagnosed with high Gleason-score PCa and those patients
with high miR-221 levels developed CRPC much earlier (10
versus 46months) [137]. Furthermore, the authors observed a
significantly lower overall survival in patients with high levels
of miR-7 and, therefore, it is suggested that miR-221 andmiR-
7 can serve as potential predictive biomarkers in advanced
prostate cancer [137]. Independently, Kneitz et al. reported
that miR-221 in prostate cancer tissue is an independent
predictor for cancer-related death and suggested thatmiR-221
offers a novel tissue-based predictive biomarker and possibly
therapeutic target in high-risk PCa [138].
Recently, Huang et al. demonstrated that single-
nucleotide polymorphisms (SNPs) in microRNAs or
miRNA target sites can act as a useful predictive biomarker.
The authors found two SNPs (rs2043556 in miR-605
and rs3737336 in the 3󸀠UTR of CDON) to be associated
with biochemical recurrence after radical prostatectomy
(𝑃 < 0.05) [139]. SNP rs3737336 lays in in silico analysis
within putative target sites of CDON for miR-181a, miR-
181b, miR-181c, miR-181d, miR-4262, and miR-5007 [139].
Furthermore, the authors observed an increased risk for
biochemical recurrence with cumulative number of risk
alleles; two risk alleles and 3 or 4 risk alleles had 1.55-fold
(𝑃 = 0.009) and 2.53-fold (𝑃 < 0.001) increased risk of
biochemical recurrence, respectively [139]. Hulf et al. found
that miR-205 DNA methylation is significantly associated
with biochemical recurrence and the authors suggest that
miR-205 is an epigenetically regulated tumor suppressor
[83].
2.6. microRNAs as Therapeutic Response. The improvement
of therapy modalities leads to a need for markers that can
help decide the best therapy for the individual patient. In
addition, markers are needed for monitoring, that is, to
evaluate early therapeutic response, to monitor effectiveness
of a treatment, and to predict chemoresistance [140, 141].
Only a few studies have investigated the levels of (circulating)
miRNAs as therapeutic markers. The investigations that
evaluated potential biomarkers in metastatic PCa and/or
CRPC are limited by the number of patients and tested
miRNAs [9, 109–111, 118]. In these studies, the researcher
investigated upregulated circulating miRNAs in serum of
CRPC patients that are applicable candidates as markers for
therapeutic response. Nguyen et al. [109] demonstrated that
miR-375, miR-378∗, and miR-141 were significantly higher
in serum of CRPC patients compared to serum of low risk
patients with a localized PCa. Zhang et al. [110] reported that
serum levels of miR-21 are higher in patients with CRPC
compared to patients with an androgen-dependent PCa and
these patients with low levels of serum PSA had also levels of
miR-21 similar to patients with a localized PCa or BPH [110].
Furthermore, Cheng et al. [111] confirmed the previous results
and found that miR-141 (𝑃 < 0.0001), miR-200a (𝑃 = 0.007),
miR-200c (𝑃 = 0.017), miR-375 (𝑃 = 0.009), and miR-210
(𝑃 = 0.022) were significantly elevated in serum of CRPC
patients compared to age-matched controls [111].
Until now, only Lin et al. determined an association of
circulating microRNAs and docetaxel chemotherapy out-
come of CRPC patients (𝑛 = 97) [9]. The authors iden-
tified 14 miRNAs out of 46 to be associated with overall
survival or PSA response to chemotherapy. Nonresponders
to docetaxel and patients with a shorter survival had high
levels of miR-200 family members prior to chemotherapy
or decreased/unchanged levels of miR-17 family members
after docetaxel treatment and therefore the authors associated
high levels of miR-200 family members in serum with poor
chemotherapy outcome of CRPC patients [9]. Furthermore,
Gonzales et al. [118] analyzed miR-141, which is a member
of the miR-200 family, together with circulating tumor cells
(CTCs), lactate dehydrogenase (LDH), and PSA in serum of
21 PCa patients and examined the utility of miR-141 alone or
in combination with CTCs, LDH, and PSA as a predictive
marker and response to therapy. The authors found a strong
correlation between clinical course according to progression
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and nonprogression of PCa andmiR-141 levels.MiR-141 levels
predicted a clinical progression with an odds ratio of 8.3
and had a high correlation with changes of PSA (𝑅 = 0.77;
𝑃 < 0.001) and CTCs (𝑅 = 0.76; 𝑃 < 0.001) [118]. However,
independent studies are necessary to confirm these findings
and to validate treatment response.
2.7. Extracellular Vesicles as Biomarkers in Prostate Cancer.
It is known that cells are able to release several types of
extracellular vesicles, which are involved in many physiolog-
ical and pathological processes, such as immune response
and cellular differentiation [142]. Extracellular vesicles differ
mainly in their cellular origins and sizes.Themost important
extracellular vesicles released from cells are apoptotic bodies,
exosomes, and shed microvesicles (MVs). Apoptotic bodies
are released from the cell membrane as a final consequence
of cell fragmentation during apoptosis [142]. They have an
irregular shape and a size of 1–5𝜇m [143, 144]. Exosomes
have a size of 30–100 nm and are released by the fusion of
multivesicular bodies (MVB) with the plasma membrane
[143, 144]. Shed MVs, which are 100–1000 nm in size, are
released by outward budding or blebbing of the plasma
membrane [142]. Extracellular vesicles can be isolated from
all body fluids, for example, blood, urine, semen, ascites, and
malignant pleural effusion [125, 142] and they contain specific
nucleic acids (e.g., miRNAs, mRNAs) and proteins, including
enzymes, which represent their tissue origin.
Recent findings indicate that extracellular vesicles are not
only waste products from cells. Exosomes and MVs that
are released from viable cells are involved in intercellular
communication in physiological as well as in pathological
processes (e.g., cancer) [143]. Exosomes, actively secreted in
vitro and in vivo, are involved in immune systemmodulation,
regulation of neuronal cell functions, and cancer progres-
sion. Exosomes released from tumor cells can contribute to
metastasis, stimulate angiogenesis, and can deliver proonco-
genic miRNAs to target cells [142, 145–147]. All exosomes
contain characteristic surface protein markers which enable
their identification [6], such as CD9 [148], CD81 [149], and
PDCD6IP [150].
Also MVs, which are characterized with high levels
of phosphatidylserine in their membranes, contribute to
cancer progression. MVs are, for example, able to modify
the extracellular matrix through the involvement of lytic
enzymes that are present in MVs [142, 151]. Through the
transfer of enzymesMVs are also able to transformfibroblasts
and epithelial cells to adopt typical cancer characteristics
[152] and MVs can be involved in drug resistance through
accumulation of antitumoral drugs [153].
In the literature another subpopulation of microvesicles,
called prostasomes, has been described. Prostasomes are
vesicles, derived from the prostate gland, that have a size of
50–500 nm (mean diameter 150 nm) and are present in high
concentrations in seminal and prostatic fluids [154]. Some
authors have hypothesized that prostasomes are just prostate-
derived exosomes. Prostasomes are secreted by normal and
malignant prostate acinar cells [155] after MVB fusion with
membranes like exosomes, but they differ from exosomes
according to their size and composition (e.g., membrane
lipids). Like all extracellular vesicles, prostasomes are also
involved in exchange of information. In physiological con-
ditions, the recipient cells are mainly spermatozoa [156]. In
addition, prostasomes are also involved in PCa progression
[156] through an inhibition of the immune system, inhibition
of the complement system, induction ofmigration by fibrino-
gen phosphorylation (protein kinases A and C), induction of
invasion, and induction of angiogenesis [142]. Tavoosidana et
al. evaluated the use of prostasomes as biomarkers and found
elevated levels of these vesicles in semen of PCa patients,
which were correlated with a higher Gleason-score of the
tumor [157]. Furthermore, prostasomes were also found in
plasma from PCa patients [142] suggesting their potential as
biomarker.
Despite a clear difference in cell origin and size, extracel-
lular vesicles are often overlapping according to their function
and features. The currently available isolation techniques
make it difficult to separate the subpopulations [142]. It
was recently reported that tumor-derived circulating exo-
somes also contain miRNAs, which can downregulate their
target genes in recipient cells [142]. Circulating exosomal
miRNAs were correlated with miRNAs identified in tissue
of ovarian cancer [158, 159] and lung cancer [160]. These
results suggest that circulating exosomal miRNAs could
potentially be used as diagnostic markers also in PCa [161].
The PCa specific gene fusion TMPRSS2-ERG, which is found
in 50% of clinically localized PCa and which is associated
with lethal PCa, is also present in exosomes isolated from
VCaP cells (an androgen responsive PCa cell line) [162,
163]. Beside blood also urine, which contains exfoliated PCa
cells and PCa-secreted products, is a promising resource
for diagnostic markers. It is reported that urine from PCa
patients contains more exosomes compared to patients with
an indolent PCa or nonmalignant disease. In PCa patients,
both PCA3 and TMPRSS2-ERG were reported in urinary
exosomes, showing that microvesicles may contain disease-
specific molecules which then can serve as promising novel
biomarkers [164]. However, PCA3 and TMPRSS2-ERG were
not detectable in exosomes from patients with ADT or in
patients with bone metastasis after radical prostatectomy
[164]. The currently used protocols for exosome isolation are
time-consuming, including a series of (ultra) centrifugation
steps and nanomembrane ultrafiltration. Further studies are
necessary to establish new and faster methods for exosome
isolation to enable fast and simple detection in routine clinical
practice. The clinical relevance of circulating and urinary
exosomes and prostasomes in semen as biomarkers for PCa
needs to be evaluated.
2.8. Circulating Tumor Cells in Prostate Cancer. The impor-
tance of circulating tumor cells (CTCs) detection and molec-
ular characterization is becoming evident. These cells can
provide significant information for a better understanding
of tumor biology and tumor cell dissemination [165]. CTC
detection may be a useful approach for monitoring disease
progression. CTCs have been shown to be the strongest
independent predictor of overall survival in comparison to
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posttherapy PSA. CRPC patients with more than 5 CTCs
in 7.5mL blood have a significantly reduced overall survival
compared to patients with less than 5 CTCs in 7.5mL blood
[166]. These results were confirmed in other studies [167,
168]. CTC detection remains a major technical challenge.
Currently, the use for diagnosis and monitoring is limited by
costly CTC isolation procedures and the lownumber of CTCs
in blood. However, technical advances could lead to novel
possibilities.
The clinical utility of monitoring CTCs is currently being
tested in large phase III trials with PCa patients being
treated with the novel antiandrogen abiraterone acetate or
the novel androgen receptor antagonist enzalutamide (a.k.a.
MDV3100). Molecular determinants can be identified and
characterized in CTCs as potential predictive biomarkers
of tumor sensitivity to a therapeutic modality [165, 169].
Potential miRNA biomarkers were also identified in CTCs.
Sieuwerts et al. found that, for example, miR-183 is expressed
in CTCs of metastatic breast cancer patients [170]. Whether
CTCs of PCa patients express specific ncRNAs remains to be
investigated.
3. Conclusion
To improve the management of PCa patients, novel diag-
nostic, predictive, and prognostic biomarkers are needed.
The ideal biomarker should be able to detect the presence
of a disease and predict its progression (i.e., identify high
risk individuals), predict recurrence, and monitor therapy
response. PCa and especially CRPC are heterogeneous dis-
eases and, therefore, it is not expected that a single biomarker
for all stages of the disease will be identified. Multiple
biomarkers, or panels of markers, will be needed to address
each particular clinical question.
The lncRNA PCA3 has already been successfully trans-
lated into clinical setting, especially to predict (repeat) biopsy
outcome of patients with elevated serum PSA. Recent studies
showed the potential of other ncRNAs, especially the miR-
NAs, as novel biomarkers for PCa. Across independent stud-
ies, elevated serum levels of miR-141 and miR-375 have been
consistently found and confirmed for metastatic PCa and/or
CRPC.These miRNAs are associated with further prognostic
parameters like higher Gleason-score and positive lymph
node status. There are a number of additional promising
miRNAs and other biomarkers, such as exosomes and CTCs,
for PCa on the horizon, but these await further validation
in independent studies. Only then, these biomarkers can be
translated into clinical practice.
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